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Abstract
Apart from periampullary carcinoma, the prognosis of biliary 
tract carcinomas, including hilar cholangiocarcinoma, extra-
hepatic biliary tract carcinoma, and gallbladder carcinoma, 
remains poor. Sophisticated diagnostic skills and treatment 
methods and their application are naturally required to 
achieve better treatment results for biliary tract carcinomas. 
However, it is not too much to say that, due to the paucity of 
high-level evidence for the management of these carcinomas, 
medical care by healthcare providers in clinics and at medical 
institutes throughout the world is currently delivered without 
common consensus and common standards. The clinical prac-
tice guidelines for the management of biliary carcinoma out-
lined here were produced with the aim that they could be used 
by physicians involved in the care of biliary tract carcinomas, 
as indicators that could help them provide their patients with 
the most appropriate care possible at this time. Also, the 
guidelines were prepared to provide measures that could 
assure patients with biliary tract carcinomas of safe medical 
care. The present guidelines are characterized by their clariﬁ  -
cation of clinical questions assumed to be often shared by 
healthcare professionals. For clarity, we divided the contents 
of the guidelines into eight areas. In each area, clinical ques-
tions are presented, together with recommendations of clini-
cal actions in response to the question. As mentioned already, 
there is a paucity of high-level evidence in this area; therefore, 
the recommendations are classiﬁ  ed into grades, of which there 
are ﬁ  ve: A, strongly recommend performing the clinical action; 
B, recommend performing the clinical action; C1, the clinical 
action may be useful, although there is a lack of high-level 
scientiﬁ  c evidence; C2, clinical action not deﬁ  nitively recom-
mended because of insufﬁ  cient scientiﬁ  c evidence; D, recom-
mend not performing the clinical action. The grading of the 
recommendations is based on the determination of the level 
of evidence in references on which the recommendation is 
based.
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Purpose of the clinical practice guidelines for the 
management of biliary tract and ampullary carcinomas 
(the guidelines)
No guidelines for the diagnosis and treatment of biliary 
tract carcinoma, the prognosis of which remains poor, 
have been published to date, although a set of guidelines 
for intrahepatic cholangiocarcinoma was published in 
2002 by Khan et al.
1 There remain many problems to be 
solved concerning the diagnosis and treatment of biliary 
tract carcinoma so that better treatment results can be 
achieved for this disease. We (The Japanese Society of 
Hepato-Biliary-Pancreatic Surgery [JSHBPS]) pro-
duced the present guidelines, recognizing that a high 
level of expertise is required for those concerned with 
the diagnosis and treatment of the disease. The greatest 
obstacle encountered most frequently in preparing the 
present guidelines was the paucity of high-level evidence 
for the diagnosis and treatment of biliary tract carci-
noma and the lack of practical guidelines for coping with 
this problem. Currently, under these circumstances, there 
are wide disparities in the levels of diagnosis and treat-
ment among different institutions. However, in assessing 
the strength of recommendations for treatment, because 
of the paucity of high-level evidence in this ﬁ  eld, the 
members of the Organizing Committee formed for cre-
ating the guidelines focused on building a concensus. 
Occasionally, decisions were subject to modiﬁ  cations on 
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the basis of discussions at an open forum. The aim of the 
guidelines was to supply indicators to physicians involved 
in the care of this disease, to provide their patients with 
the safest and most appropriate care.
Notes on the use of the guidelines
The entire contents of the present guidelines were 
endorsed upon discussions held among all the members 
of the Organizing Committee and the Publishing Com-
mittee. The guidelines consist of algorithms that outline 
diagnosis and treatment, followed by clinical questions. 
In view of the fact that there is still a wide variation in 
treatment policies among medical institutions, the pre-
sentation of the contents is made in the form of clinical 
questions.
2,3 The contents are divided into eight areas to 
elucidate the clinical questions considered to be shared 
by healthcare professionals and to clarify the guidelines 
with respect to these questions at this stage of publica-
tion. The questions in each area are presented under the 
heading of “clinical questions.” The presence or absence 
of recommendations for a clinical action, the strength 
of the recommendations, and statements on how recom-
mendations are made are provided with each question. 
Recommendations and statements are formulated on 
the basis of evidence. The strength of treatment recom-
mendations in response to each question was deter-
mined in accordance with the following policy. Compared 
with breast cancer and gastric cancer, only a limited 
amount of high-level evidence has been obtained from 
randomized controlled trials for the diagnosis and treat-
ment of biliary tract carcinoma. As a result, we aimed 
to reach a consensus on the grading of the strength of 
recommendations. This was done and the strength of 
recommendations was stated according to ﬁ  ve grades:
A, Strongly recommend performing the clinical action.
B, Recommend performing the clinical action.
C1, Clinical action may be useful although there is a lack 
of high-level scientiﬁ  c evidence.
C2, Not deﬁ  nitively recommended, because of insufﬁ  -
cient scientiﬁ  c evidence.
D, Recommend not performing the clinical action.
Perspective on “guidelines”
With regard to the present guidelines, from the perspec-
tive of “guidelines,” they represent the most standard 
clinical and practical indicators at this time. However, 
they should not be coercive for the practical manage-
ment of individual patients. Final decisions on manage-
ment should be made on the basis of conditions at 
individual institutions (depending on personnel, experi-
ence, instruments, etc.) and the individual characteris-
tics of patients.
The Japanese Society of Hepato-Biliary-Pancreatic 
Surgery (JSHBPS) is responsible for the statements in 
the present guidelines. The JSHBPS and the Organizing 
Committee members are not liable for any consequences 
arising from any treatment, for which individual physi-
cians involved in the treatment should be responsible. 
The dosages described in the text are for adult 
patients.
How the guidelines were formulated
With evidence-based medicine (EBM) as the core 
concept, the ﬁ  rst Preparation Committee for “the guide-
lines for the management of biliary tract carcinoma” 
was held on May 12, 2005, to discuss how to formulate 
the guidelines. The guidelines were prepared according 
to the following procedures: (1) Comprehensive search 
using key words for relevant literature on biliary tract 
carcinoma in the past 20 years. (2) Assessment and clas-
siﬁ  cation of the abstracts of all retrieved articles, on the 
basis of contents, by at least two reviewers, and selec-
tion of literature considered useful. (3) Using the 
selected literature as reference matter, each committee 
member prepared a draft of clinical questions in the 
area in which he or she was involved. (4) From all 
the questions selected by all committee members, clini-
cal questions considered appropriate were selected at 
the general meeting. (5) Preparation of statements on 
clinical questions of each specialty. (6) Review of the 
presence/absence of recommendations, strength of rec-
ommendations and statements proposed at the general 
meeting, and checking of the contents of statements. (7) 
Check of the ﬁ  nal draft by all committee members. (8) 
Assessment by the members of the Review Committee 
of the draft prepared according to the above proce-
dures. (9) A public hearing was held to hear opinions 
from an audience with wide medical specialties. (10) 
New committee members of the Publishing Committee 
were elected from the Organizing Committee to further 
review the ﬁ  nal draft. So that the draft would be objec-
tive and evidence-based, it was further checked for con-
sistency in the strength of recommendations and 
statements of clinical questions. The statements were 
modiﬁ  ed to be more readable. Thus, the ﬁ  nal draft was 
prepared.
Comprehensive literature search
References written in English were searched for on 
MEDLINE in June 2005. Reference formulas used and 
the number of items retrieved are shown below. Sys-
tematic review articles were also searched for using the 
formulas below. References were further searched for, 
where necessary, by means of a manual search.4  T. Takada et al: Background of guidelines for biliary cancer
Search for English-language references
1. Biliary tract neoplasms [MeSH] limits: publication 
date from 1985, English, humans.
2. Publication types: Clinical trial or Meta-analysis or 
Practice Guideline or Randomized Controlled Trial 
or Review — 1266 items.
Systematic reviews
Cochrane library: key word “biliary” 59 items.
MEDLINE:
Search 1. “biliary tract neoplasms” [MeSH] limits: only 
items with abstracts, English, publication date from 
1985 to 2006, Clinical Trial, Meta-analysis, Random-
ized Controlled Trial, Review — 1136 items
Search 2. “biliary tract neoplasms” [MeSH] or “gall-
bladder cancer” or “common bile duct cancer” limits: 
English, publication date from 1985 to 2006, humans 
— 491 items
Search 3. (((((((((((“Meta-Analysis” [MeSH terms] or 
meta-analysis[pt]) or medline [tiab]) or ((((metaanal-
yses [tiab] or metaanalysis[tiab]) or metaanalytic[tiab]) 
or metaanalytical [tiab]) or metaanalytically [tiab])) 
or “metaanalysis” [All Fields]) or (((((overview [tiab] 
or overview/literature [tiab]) or overviewed [tiab]) or 
overviewer [tiab]) or overviewing [tiab]) or overviews 
[tiab])) or clinical trial [pt]) or multicenter study[pt]) 
or evaluation studies[pt]) or validation studies [pt]) 
or review [pt]) or (systematic review [All Fields] or 
systematic reviews [All Fields])) — 182 7246 items
Search 2 and Search 3, but not Search 1, — 314 items
Final selection of appropriate references by Publishing 
Committee members
On the basis of an evaluation by at least two Publishing 
Committee members of the importance of abstracts of 
selected references, 669 English-language references 
were ﬁ  nally selected.
Preparation of drafts of clinical questions
Using the literature thus selected as references, drafts 
of clinical questions were prepared by the responsible 
Publishing Committee members, and 227 questions in 
total were proposed.
Final selection of clinical questions from the drafts
At a general meeting held on July 10, 2006, the decision 
was made that 33 clinical questions should be adopted 
for each of the eight specialized areas.
Preparation of statements for clinical questions
The statements of clinical questions and introductions 
were prepared for each specialized area by the respon-
sible Publishing Committee members. Another general 
meeting was held and the number of clinical questions 
to be adopted was changed to 35.
The strength of recommendations for individual clini-
cal questions was given in related statements. Determi-
nation of the level of evidence for individual references, 
on which the strength of recommendations was deter-
mined, was made according to the criteria shown in 
Tables 1 and 2. In view of the lack of high-level evidence 
on the treatment of biliary tract carcinoma, the deci-
sions on treatment policies were made by taking into 
account the ﬁ  ndings collected from case studies.
Strength of recommendations and evaluation of 
evidence levels (Tables 1 and 2)
The “grade of recommendations” was discussed many 
times at an Organizing Committee meeting and at a 
second public hearing meeting. There are many criteria 
for the strength of recommendations in many clinical 
practice guidelines, and there are no worldwide stan-
dards. After all the discussions, we were able to reach 
the following consensus on the grading of the strength 
Table 1.  Strength of recommendations
A, Strongly recommend performing the clinical action
B, Recommend performing the clinical action
C1, The clinical action may be considered although there is 
a lack of high-level scientiﬁ  c evidence for its use. May be 
useful
C2, Clinical action not deﬁ  nitively recommended because of 
insufﬁ  cient scientiﬁ  c evidence. Evidence insufﬁ  cient to 
support or deny usefulness
D, Recommend not performing the clinical action
Table 2.  Levels of evidence
Level I Systematic review/meta-analysis
Level II One or more randomized clinical trials
Level III Nonrandomized controlled trials
Level IV Analytic epidemiology (cohort studies and case-control studies)
Level V Descriptive study (case reports and case-series studies)
Level VI Opinions of expert panels and individual experts not based on 
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of recommendations. The aim of the grading of recom-
mendations is to present indicators which will help phy-
sicians involved in the care of patients with biliary tract 
carcinoma to provide their patients with the safest and 
most appropriate care.
Decisions on clinical questions and 
review of algorithms
The statements for the clinical questions were modiﬁ  ed 
by the responsible Publishing Committee members. A 
further general meeting was held to review all the 
clinical questions. The ﬁ  nal number of questions was 
changed to 36. Diagnosis and treatment algorithms were 
also prepared.
Evaluation by Review Committee members
Evaluations and suggestions for the ﬁ  nal draft were 
made by the External Review Committee.
Additions and modiﬁ  cations were made after discus-
sions by the Publishing Committee members.
Public hearing
At two public hearings (the ﬁ  rst on June 7, 2007; the 19
th 
Annual Meeting of the JSHPBS, and the second, on 
September 29, 2007; the 43
rd Annual Meeting of Japan 
Biliary Association), comments were requested from 
the audience, particularly from physicians from a wide 
area of medical specialties, and then the ﬁ  nal correc-
tions of the draft were made.
Publishing Committee
The Publishing Committee was organized after the ﬁ  rst 
public hearing. Reexaminations, additions, and correc-
tions were made with respect to all the expressions, 
sentences, and terminology, etc., by all the Publishing 
Committee members. For the contents, repeated dis-
cussions were held until a sufﬁ  cient consensus was 
achieved.
The ﬁ  nal version of the ﬁ  nal draft was made public at 
the second public hearing, and comments from the 
general audience were requested. The ﬁ  nal version was 
also evaluated by the External Review Committee 
members. The draft was ﬁ  nalized taking into account 
these comments and the evaluation.
Diffusion of the guidelines
The guidelines, Evidence-based clinical practice guide-
lines for the management of biliary tract carcinoma, were 
published in Japanese by Igaku-Tosyo Syuppan.
The guidelines were posted on the Internet on the 
JSHBPS home page, Japan Council for Quality Health 
Care; and, on the medical information network distribu-
tion service (Minds) home page.
Plan for publication of the revised edition
Evaluation and accumulation of pertinent evidence is 
being continued by the Organizing Committee of the 
guidelines, which has been established permanently at 
the JSHBPS. A revised edition is expected to be pub-
lished every 4 years, but the timing of the revisions will 
be subject to change depending upon advances in 
medical science and care.
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